{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06163534",
            "orgStudyIdInfo": {
                "id": "TP-CA-006"
            },
            "secondaryIdInfos": [
                {
                    "id": "Pro00074943",
                    "type": "OTHER",
                    "domain": "Advarra"
                }
            ],
            "organization": {
                "fullName": "Tempus AI",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)",
            "officialTitle": "TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-longitudinal-multi-omic-biomarker-profiling-study-of-patients-with-head-neck-squamous-cell-carcinoma-hnscc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-03-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-03-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-07",
            "studyFirstSubmitQcDate": "2023-11-30",
            "studyFirstPostDateStruct": {
                "date": "2023-12-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Tempus AI",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "AstraZeneca",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Head and Neck Squamous Cell Carcinoma"
            ],
            "keywords": [
                "Oncology",
                "Biomarkers",
                "Genomic Profiling",
                "HNSCC",
                "Cancer",
                "Observational",
                "Registry",
                "Precision Medicine",
                "NGS"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": true,
            "targetDuration": "1 Year",
            "designInfo": {
                "observationalModel": "OTHER",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "Blood and tissue will be collected."
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Metastatic or unresectable recurrent HNSCC",
                    "description": "Up to 500 participants (including primary tumor location of pharynx, larynx, oral cavity and oropharynx) with metastatic or unresectable recurrent HNSCC who are intended for first line immunotherapy or combination therapy. No intervention."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Explore DNA, RNA, immune and other multiomic biomarkers to better understand prognostic or predictive biomarkers and to inform future research for new relevant biomarkers.",
                    "description": "Use NGS, ctNDA assessments, RNA analysis, and other multiomic testing to uncover biomarkers of collected blood and tissue samples that may predict outcomes, identify markers related to disease, identify markers related to mechanism of drug action, and inform future research.",
                    "timeFrame": "5 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Explore changes in relevant DNA, RNA, immune and multiomic biomarkers in longitudinal blood samples, and diagnostic and progression biopsy samples, to understand real-world outcomes and resistance mechanisms.",
                    "description": "Correlate biomarkers of collected blood and tissue samples with standard of care therapy real-world outcomes such as overall survival, progression free survival, time to next treatment, and time to treatment discontinuation.",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Explore changes in ctDNA from longitudinal blood samples to assess ctDNA as a response biomarker.",
                    "description": "Assess changes in ctNDA of collected blood samples using ctDNA clearance factors such as time to clearance, best overall clearance rate, best confirmed clearance, duration, time to ctDNA recurrence with standard of care therapy real-world outcomes such as overall survival, progression free survival, time to next treatment, and time to treatment discontinuation.",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \u226518 years of age\n* Willing and able to provide informed consent\n* Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies\n* Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy\n* Must submit fresh or archived block tumor sample representative of current disease per laboratory manual\n\nExclusion Criteria:\n\n* Non-squamous histologies (eg, nasopharynx or salivary gland)\n* Relapse or recurrence within 6 months of first line chemotherapy and / or chemoradiotherapy\n* Tumors that are PD-L1 negative (CPS \\<1)\n* Clinical evidence of an active second invasive malignancy within \\<2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers\n* Unable to comply with study procedures (i.e., not willing or able to have additional blood samples collected)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "This protocol targets patients with metastatic or unresectable, recurrent HNSCC intended for first line immunotherapy or combination therapy.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Phoenix HNSCC",
                    "role": "CONTACT",
                    "phone": "(833) 514-4187",
                    "email": "phoenix@tempus.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Virginia Rhodes, MD",
                    "affiliation": "Tempus AI, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Ursu",
                            "role": "CONTACT",
                            "email": "sursu@coh.org"
                        },
                        {
                            "name": "Victoria Villaflor",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Oncology Hematology Associates",
                    "status": "RECRUITING",
                    "city": "Springfield",
                    "state": "Missouri",
                    "zip": "65807",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Adrianna Moore",
                            "role": "CONTACT",
                            "phone": "417-882-4880",
                            "email": "adrianna.moore@aoncology.com"
                        },
                        {
                            "name": "V. Roger Holden, MD, PHD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.21533,
                        "lon": -93.29824
                    }
                },
                {
                    "facility": "Cancer Care Associates of York",
                    "status": "RECRUITING",
                    "city": "York",
                    "state": "Pennsylvania",
                    "zip": "17403",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clarissa Vega",
                            "role": "CONTACT",
                            "email": "cvega@cancercareyork.com"
                        },
                        {
                            "name": "Chanh Huynh",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.9626,
                        "lon": -76.72774
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "34540672",
                    "type": "BACKGROUND",
                    "citation": "Hsieh RW, Borson S, Tsagianni A, Zandberg DP. Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Front Oncol. 2021 Sep 1;11:705614. doi: 10.3389/fonc.2021.705614. eCollection 2021."
                },
                {
                    "type": "BACKGROUND",
                    "citation": "Head and neck cancer - risk factors and prevention. Cancer.Net. Published June 25, 2012. Accessed August 11, 2023. https://www.cancer.net/cancer-types/head-and-neck-cancer/risk-factors-and-prevention"
                },
                {
                    "pmid": "26046059",
                    "type": "BACKGROUND",
                    "citation": "Kimple RJ, Harari PM. The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy. Ann Transl Med. 2015 May;3(Suppl 1):S14. doi: 10.3978/j.issn.2305-5839.2015.01.37. No abstract available."
                },
                {
                    "pmid": "34069092",
                    "type": "BACKGROUND",
                    "citation": "Ionna F, Bossi P, Guida A, Alberti A, Muto P, Salzano G, Ottaiano A, Maglitto F, Leopardo D, De Felice M, Longo F, Tafuto S, Della Vittoria Scarpati G, Perri F. Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. Cancers (Basel). 2021 May 14;13(10):2371. doi: 10.3390/cancers13102371."
                },
                {
                    "pmid": "29941547",
                    "type": "BACKGROUND",
                    "citation": "Samra B, Tam E, Baseri B, Shapira I. Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives. J Investig Med. 2018 Oct;66(7):1023-1030. doi: 10.1136/jim-2018-000743. Epub 2018 Jun 25."
                },
                {
                    "pmid": "18784101",
                    "type": "BACKGROUND",
                    "citation": "Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656."
                },
                {
                    "pmid": "31679945",
                    "type": "BACKGROUND",
                    "citation": "Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr, Psyrri A, Baste N, Neupane P, Bratland A, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, Gonzalez Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Erratum In: Lancet. 2020 Jan 25;395(10220):272. doi: 10.1016/S0140-6736(20)30116-1. Lancet. 2020 Feb 22;395(10224):564. doi: 10.1016/S0140-6736(20)30254-3. Lancet. 2021 Jun 12;397(10291):2252. doi: 10.1016/S0140-6736(21)01119-3."
                },
                {
                    "pmid": "33076306",
                    "type": "BACKGROUND",
                    "citation": "Wang HC, Yeh TJ, Chan LP, Hsu CM, Cho SF. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. Int J Mol Sci. 2020 Oct 15;21(20):7621. doi: 10.3390/ijms21207621."
                },
                {
                    "pmid": "30115704",
                    "type": "BACKGROUND",
                    "citation": "Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16."
                },
                {
                    "pmid": "30546008",
                    "type": "BACKGROUND",
                    "citation": "Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018 Dec 13;50(12):1-11. doi: 10.1038/s12276-018-0191-1."
                },
                {
                    "pmid": "36092724",
                    "type": "BACKGROUND",
                    "citation": "Yu C, Li Q, Zhang Y, Wen ZF, Dong H, Mou Y. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Front Cell Dev Biol. 2022 Aug 26;10:941750. doi: 10.3389/fcell.2022.941750. eCollection 2022."
                },
                {
                    "pmid": "33919778",
                    "type": "BACKGROUND",
                    "citation": "Kong L, Birkeland AC. Liquid Biopsies in Head and Neck Cancer: Current State and Future Challenges. Cancers (Basel). 2021 Apr 14;13(8):1874. doi: 10.3390/cancers13081874."
                },
                {
                    "pmid": "26786940",
                    "type": "BACKGROUND",
                    "citation": "Mazurek AM, Rutkowski T, Fiszer-Kierzkowska A, Malusecka E, Skladowski K. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol. 2016 Mar;54:36-41. doi: 10.1016/j.oraloncology.2015.12.002. Epub 2016 Jan 11."
                },
                {
                    "pmid": "24553385",
                    "type": "BACKGROUND",
                    "citation": "Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094."
                },
                {
                    "pmid": "26109104",
                    "type": "BACKGROUND",
                    "citation": "Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015 Jun 24;7(293):293ra104. doi: 10.1126/scitranslmed.aaa8507."
                },
                {
                    "pmid": "25078109",
                    "type": "BACKGROUND",
                    "citation": "Ahn SM, Chan JY, Zhang Z, Wang H, Khan Z, Bishop JA, Westra W, Koch WM, Califano JA. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014 Sep;140(9):846-54. doi: 10.1001/jamaoto.2014.1338."
                },
                {
                    "pmid": "28792880",
                    "type": "BACKGROUND",
                    "citation": "Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, Chu SWI, Mak C, Tse IOL, Leung SYM, Chan G, Hui EP, Ma BBY, Chiu RWK, Leung SF, van Hasselt AC, Chan ATC, Lo YMD. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med. 2017 Aug 10;377(6):513-522. doi: 10.1056/NEJMoa1701717. Erratum In: N Engl J Med. 2018 Mar 8;378(10):973. doi: 10.1056/NEJMx180004."
                },
                {
                    "pmid": "15928666",
                    "type": "BACKGROUND",
                    "citation": "Hamana K, Uzawa K, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Tanzawa H. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer. 2005 Jun 20;92(12):2181-4. doi: 10.1038/sj.bjc.6602635."
                },
                {
                    "pmid": "32017652",
                    "type": "BACKGROUND",
                    "citation": "Chera BS, Kumar S, Shen C, Amdur R, Dagan R, Green R, Goldman E, Weiss J, Grilley-Olson J, Patel S, Zanation A, Hackman T, Blumberg J, Patel S, Thorp B, Weissler M, Yarbrough W, Sheets N, Mendenhall W, Tan XM, Gupta GP. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. J Clin Oncol. 2020 Apr 1;38(10):1050-1058. doi: 10.1200/JCO.19.02444. Epub 2020 Feb 4. Erratum In: J Clin Oncol. 2020 Oct 20;38(30):3579. doi: 10.1200/JCO.20.02655. J Clin Oncol. 2023 Sep 20;41(27):4449. doi: 10.1200/JCO.23.01228."
                },
                {
                    "pmid": "35740633",
                    "type": "BACKGROUND",
                    "citation": "Aulakh SS, Silverman DA, Young K, Dennis SK, Birkeland AC. The Promise of Circulating Tumor DNA in Head and Neck Cancer. Cancers (Basel). 2022 Jun 16;14(12):2968. doi: 10.3390/cancers14122968."
                },
                {
                    "pmid": "34230613",
                    "type": "BACKGROUND",
                    "citation": "Liebs S, Eder T, Klauschen F, Schutte M, Yaspo ML, Keilholz U, Tinhofer I, Kidess-Sigal E, Braunholz D. Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities. Oncogene. 2021 Aug;40(33):5204-5212. doi: 10.1038/s41388-021-01928-w. Epub 2021 Jul 6."
                },
                {
                    "pmid": "32460897",
                    "type": "BACKGROUND",
                    "citation": "Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, Pantano F, Dell'Aquila E, Anesi C, Silvestris N, Argentiero A, Solimando AG, Vincenzi B, Tonini G, Santini D. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020 May 27;39(1):95. doi: 10.1186/s13046-020-01601-2. Erratum In: J Exp Clin Cancer Res. 2020 Jun 24;39(1):120. doi: 10.1186/s13046-020-01615-w."
                },
                {
                    "pmid": "33508232",
                    "type": "BACKGROUND",
                    "citation": "Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A, Lim E, Al Bakir M, Turati V, Guerra-Assuncao JA, Conde L, Furness AJS, Saini SK, Hadrup SR, Herrero J, Lee SH, Van Loo P, Enver T, Larkin J, Hellmann MD, Turajlic S, Quezada SA, McGranahan N, Swanton C. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021 Feb 4;184(3):596-614.e14. doi: 10.1016/j.cell.2021.01.002. Epub 2021 Jan 27."
                },
                {
                    "pmid": "32042196",
                    "type": "BACKGROUND",
                    "citation": "Fairfax BP, Taylor CA, Watson RA, Nassiri I, Danielli S, Fang H, Mahe EA, Cooper R, Woodcock V, Traill Z, Al-Mossawi MH, Knight JC, Klenerman P, Payne M, Middleton MR. Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat Med. 2020 Feb;26(2):193-199. doi: 10.1038/s41591-019-0734-6. Epub 2020 Feb 10."
                },
                {
                    "pmid": "32110781",
                    "type": "BACKGROUND",
                    "citation": "Valpione S, Galvani E, Tweedy J, Mundra PA, Banyard A, Middlehurst P, Barry J, Mills S, Salih Z, Weightman J, Gupta A, Gremel G, Baenke F, Dhomen N, Lorigan PC, Marais R. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer. 2020 Feb;1(2):210-221. doi: 10.1038/s43018-019-0022-x. Epub 2020 Feb 10."
                },
                {
                    "pmid": "33007267",
                    "type": "BACKGROUND",
                    "citation": "Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, Jeon YJ, Tseng D, Liu C, Merghoub T, Neal JW, Wakelee HA, Padda SK, Ramchandran KJ, Das M, Plodkowski AJ, Yoo C, Chen EL, Ko RB, Newman AM, Hellmann MD, Alizadeh AA, Diehn M. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020 Oct 15;183(2):363-376.e13. doi: 10.1016/j.cell.2020.09.001. Epub 2020 Oct 1."
                },
                {
                    "pmid": "31040929",
                    "type": "BACKGROUND",
                    "citation": "Beaubier N, Tell R, Lau D, Parsons JR, Bush S, Perera J, Sorrells S, Baker T, Chang A, Michuda J, Iguartua C, MacNeil S, Shah K, Ellis P, Yeatts K, Mahon B, Taxter T, Bontrager M, Khan A, Huether R, Lefkofsky E, White KP. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019 Mar 22;10(24):2384-2396. doi: 10.18632/oncotarget.26797. eCollection 2019 Mar 22."
                },
                {
                    "pmid": "31570899",
                    "type": "BACKGROUND",
                    "citation": "Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, Khan AA, Kudalkar E, Leibowitz BD, Lozachmeur A, Michuda J, Parsons J, Perera JF, Salahudeen A, Shah KP, Taxter T, Zhu W, White KP. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019 Nov;37(11):1351-1360. doi: 10.1038/s41587-019-0259-z. Epub 2019 Sep 30."
                },
                {
                    "pmid": "34215841",
                    "type": "BACKGROUND",
                    "citation": "Finkle JD, Boulos H, Driessen TM, Lo C, Blidner RA, Hafez A, Khan AA, Lozac'hmeur A, McKinnon KE, Perera J, Zhu W, Dowlati A, White KP, Tell R, Beaubier N. Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. NPJ Precis Oncol. 2021 Jul 2;5(1):63. doi: 10.1038/s41698-021-00202-2."
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000077195",
                    "term": "Squamous Cell Carcinoma of Head and Neck"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000018307",
                    "term": "Neoplasms, Squamous Cell"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "asFound": "Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "asFound": "Head and Neck Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M20451",
                    "name": "Neoplasms, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M251057",
                    "name": "TEMPO",
                    "relevance": "LOW"
                },
                {
                    "id": "M186190",
                    "name": "Aluminum hydroxide, magnesium hydroxide, simethicone drug combination",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                }
            ]
        }
    },
    "hasResults": false
}